-
2023-504989-37-00
5
Metastatic Squamous Non-small Cell Lung Cancer
-
2023-505311-20-00
5
Metastatic Non-Small Cell Lung Cancer
-
2024-512195-35-00
5
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521908-22-00
10
EGFR-mutated Non-small Cell Lung Cancer
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2025-522484-15-00
5
2026-04-27
ER+/HER2- early breast cancer
-
2025-523204-68-00
4
2026-03-25
HER2-positive breast cancer
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2024-516790-78-00
4
2025-09-04
stage IV NSCLC (non-small-cell lung cancer)
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer
-
2023-505172-29-00
4
2025-04-24
Resectable Non-small Cell Lung Cancer
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2023-505604-32-00
5
2024-01-24
Non small cell lung cancer (NSCLC)
-
2023-503920-14-00
5
2024-01-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2024-520290-12-00
6
2025-11-04
Hormone receptor–positive (HRpos)/human epidermal growth factor recept
-
2024-516794-70-00
4
2025-11-03
Metastatic non-squamous non-small cell lung cancer